Gonadotrophins for ovulation induction in women with polycystic ovarian syndrome
Referencias
Additional references
Albano C, Smitz J, Camus M, Coelingh Bennink H, van Steirteghem AC, Devroey P. Pregnancy and birth in an in‐vitro fertilization cycle after controlled ovarian stimulation in a women with a history of allergic reaction to human menopausal gonadotrophin. Human Reproduction 1996;11(8):1632‐4.
Baenziger JU, Green ED. Pituitary glycoprotein hormone oligosaccharides: structure, synthesis and function of asparagine‐linked oligosaccharides on lutropin, follitropin and thyrotropin. Biochimica et Biophysica Acta 1988;947:287‐306.
Bergh C. What are the clinical benefits of recombinant gonadotrophins? Recombinant follicle stimulating hormone. Human Reproduction 1999;14(6):1418‐20.
Biffoni M, Battaglia A, Borrelli F, Cantelmo A, Galli G, Eshkol A. Allergenic potential of gonadotrophic preparations in experimental animal: Relevance of purity. Human Reproduction 1994;9(10):1845‐8.
de Leeuw R, Mulders J, Voortman G, Rombout F, Damm J, Kloosterboer L. Structure‐function relationship of recombinant follicle stimulating hormone (Puregon). Molecular Human Reproduction 1996;2(5):361‐9.
Farquhar C, Brown J, Marjoribanks J. Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. 2012 Jun 13;6:CD001122.. Cochrane Database of Systematic Reviews 2012, Issue 6. [DOI: 10.1002/14651858.CD001122.pub4]
GEMZELL CA, DICZFALUSY E, TILLINGER G. Clinical effect of human pituitary follicle‐stimulating hormone (FSH).. J. Clin. Endocrinol. Metab 1958;18:1333‐48.
Gray CJ. Glycoprotein gonadotrophins. Structure and synthesis. Acta Endocrinologica. Supplementum 1988;288:20‐7.
Hard K, Mekking A, Damm JBL, Kamerling JP, de Boer W, Wijnands RA, Vliegenthart JFG. Isolation and structure determination of the intact sialylated N‐linked carbohydrate chains of recombinant human follitropin (hFSH) expressed in Chinese Hamster ovary cells. European Journal of Biochemistry 1990;193(1):263‐71.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21(11):1539‐58.
Higgins JP. Heterogeneity in meta‐analyses should be expected and appropriately quantified. International Journal of Epidemiology 2008;37:1158‐60.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Howles CM. Genetic Engineering of human FSH (Gonal F). Human Reproduction Update 1996;2:172‐91.
Hull MGR. Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecological Endocrinology 1987;1:235‐45.
Keene JL, Matzuk MM, Otani T, Fauser BC, Galway AB, Hsueh AJ, Boime I. Expression of biologically active human follitropin in Chinese hamster ovary cells. Journal of Biological Chemistry 1989;254:4769‐75.
Lambert A, Rodgers M, Mitchell R, Wood AM, Wardle C, Hilton B, Robertson WR. In‐vitro biopotency and glycoform distribution of recombinant human follicle stimulating hormone (Org 32489), Metrodin and Metrodin‐HP. Human Reproduction 1995;10(7):1928‐35.
Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326(7400):1167‐70.
Lunenfeld B, Menzi A, Volet B. Effetti clinici della gonadotropina umana della post‐menopausa. La Rassegna di Clinica, Terapia e Scienze Affini 1960;59:213‐6.
Rotterdam ESHRE/ASRM‐Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycysticovary syndrome. Human Reproduction 2004;19:41‐47.
Rotterdam ESHRE/ASRM‐Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycysticovary syndrome. Fertility and Sterility 2004;81:19‐25.
Stockell Hartree AS, Renwick AGC. Molecular structures of glycoprotein hormones and functions of their carbohydrate components. Biochemistry Journal 1992;287:665‐79.
Vail A, Gardener E. Common statistical errors in the design and analysis of subfertility trials. Human Reproduction 2003;18:1000‐4.
van Wely M, Kwan I, Burt AL, Thomas J, Vail A, Van der Veen F, Al‐Inany HG. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD005354.pub2]
Wide L. Isoforms of human gonadotrophins under different physiological conditions. Kahn JA, editor(s). Gonadotrophin isoforms: facts and future. Copenhagen: Ciconia Foundation, 1997:43‐8.
Wilson CA, Leigh AJ, Chapman AJ. Gonadotrophin glycosylation and function. Journal of Endocrinology 1990;125:3‐14.
References to other published versions of this review
Ir a:
Bayram N, van Wely M, van Der Veen F. Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2001, Issue 2. [DOI: 10.1002/14651858.CD002121]
Nugent D, Vanderkerchove P, Hughes E, Arnot M, Lilford R. Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD000410]
